関連ニュース

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. The FDA's exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull ca

Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progr

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA

Investors are closely watching Vera Therapeutics Inc. (NASDAQ:VERA) as the company awaits the U.S. Food and Drug Administration (FDA) decision for its rare kidney disease drug.